These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 14719452

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 3. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC.
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E, Sofras F.
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [Abstract] [Full Text] [Related]

  • 5. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A, Navone R.
    Cancer; 2002 Aug 15; 95(4):784-90. PubMed ID: 12209722
    [Abstract] [Full Text] [Related]

  • 6. [Prognostic value of the immunohistochemical expression of: Ki67, p53, PCNA and Bcl2 in the superficial tumors of the bladder].
    Rammeh-Rommani S, Zermani R, Sfaxi M, Chabchoub A, Zouari B, Ayed M, Ben Jilani-Baltagi S.
    Tunis Med; 2007 Jun 15; 85(6):509-12. PubMed ID: 17644907
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
    Lee SE, Chow NH, Chi YC, Tzai TS, Yang WH, Lin SN.
    Anticancer Res; 1994 Jun 15; 14(3B):1317-24. PubMed ID: 7915094
    [Abstract] [Full Text] [Related]

  • 9. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC.
    Anticancer Res; 1998 Jun 15; 18(6B):4717-21. PubMed ID: 9891547
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D, Navarro Fos S, Villamón Fort R, Gil Salom M, Llombart Bosch A.
    Arch Esp Urol; 2003 Apr 15; 56(3):277-85. PubMed ID: 12768988
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Seo HK, Cho KS, Chung J, Joung JY, Park WS, Chung MK, Lee KH.
    Urology; 2010 Aug 15; 76(2):512.e1-7. PubMed ID: 20579709
    [Abstract] [Full Text] [Related]

  • 13. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
    Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, Montironi R.
    Am J Clin Pathol; 2004 Sep 15; 122(3):444-52. PubMed ID: 15362377
    [Abstract] [Full Text] [Related]

  • 14. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S, Lange I, Kausch I, Feller AC.
    Anticancer Res; 2005 Sep 15; 25(1A):263-71. PubMed ID: 15816547
    [Abstract] [Full Text] [Related]

  • 15. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H, Sato N, Hiyama M, Kaimori M, Endo S, Sohara Y, Imai T.
    Ann Thorac Surg; 2006 Oct 15; 82(4):1198-204. PubMed ID: 16996907
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT, Sahin A, Altok M, Unlü N, Zorlu F.
    J Urol; 2007 Sep 15; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [Abstract] [Full Text] [Related]

  • 18. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
    Pich A, Margaria E, Chiusa L, Bortolin P, Palestro G.
    Oncol Rep; 2003 Sep 15; 10(5):1329-35. PubMed ID: 12883702
    [Abstract] [Full Text] [Related]

  • 19. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, Abboh CC, Mazerolles C, Chopin DK.
    Cancer; 1997 Oct 15; 80(8):1472-81. PubMed ID: 9338472
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.